P/E ratio for Mesoblast (MESO)
P/E ratio as of April 2024 (TTM): 0.1284
According to Mesoblast 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.12842. At the end of 2022 the company had a P/E ratio of 0.0797.
P/E ratio history for Mesoblast from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 0.0797 | -101.26% |
| 2021 | -6.31 | -34.96% |
| 2020 | -9.70 | -2.3% |
| 2019 | -9.93 | 115.99% |
| 2018 | -4.60 | -70.74% |
| 2017 | -15.7 | -79.11% |
| 2016 | -75.2 | 1453.08% |
| 2015 | -4.84 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | -3.33 | -2,695.65% | Bahamas |
 NRC Health
NRC | 28.8 | 22,292.38% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.